Dimitrios T. Boumpas
National and Kapodistrian University of Athens
H-index: 102
Europe-Greece
Top articles of Dimitrios T. Boumpas
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated … | Emmanouil Vrentzos George Pavlidis Konstantinos Katogiannis Emmanouil Korakas Aikaterini Kountouri | 2024/3/21 | |
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis | Rheumatology International | Christina Tsalapaki Argyro Lazarini Evaggelia Argyriou Vassiliki Dania Kyriaki Boki | 2024/2/1 |
P88 Baseline factors associated with subsequent development of incident nephritis in patients with systemic lupus erythematosus: a retrospective cohort study | Spyridon Katechis Dionysis Nikolopoulos Sofia Flouda Katerina Chavatza Noemin Kapsala | 2024/3/1 | |
Impaired serotonin synthesis in hippocampus of murine lupus represents an early neuropsychiatric event | Lupus | Dionysis Nikolopoulos Modestos Nakos-Bimpos Theodora Manolakou Alexia Polissidis Dimitrios T Boumpas | 2024/2/1 |
Persistence on subcutaneous tocilizumab as monotherapy or in combination with synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients in Greece … | Clinical Rheumatology | Panagiotis Athanassiou Pelagia Katsimbri Andreas Bounas Sοusana Gazi Theodosios Sarikoudis | 2024/3/12 |
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct … | Annals of the Rheumatic Diseases | Dionysis Nikolopoulos Catherine Loukogiannaki George Sentis Panagiotis Garantziotis Theodora Manolakou | 2024/4/12 |
P70 Exposure to DORIS≥ 50% of time and to LLDAS≥ 60% of observation time exhibit the best combination of feasibility and protection against adverse outcomes in moderate-to … | Sofia Pitsigavdaki Myrto Nikoloudaki Panagiotis Garantziotis Ettore Silvagni Argyro Repa | 2024/3/1 | |
Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2 | Rheumatology | Κonstantinos Thomas Ioannis Grigoropoulos Panagiota Alexopoulou Emmanouil Karofylakis Irene Galani | 2024/2/1 |
P100 Efficacy of anifrolumab in multi-refractory skin manifestations of systemic lupus erythematosus: case series | Sofia Flouda Evgenia Emmanouilidou Anastasios Karamanakos George Bertsias Dimitrios Boumpas | 2024/3/1 | |
The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS | Respiratory Research | Ioannis Grigoropoulos Georgios Tsioulos Artemis Kastrissianakis Shiran Shapira Orr Green | 2024/4/1 |
P92 Quantifying the unmet need in lupus nephritis: EULAR/ERA-EDTA treatment targets, flares, and treatment modifications in the first year in a multicenter observational study | Maria Pappa Maria Kosmetatou Antigone Pieta Flora Chouzouri Evangelia Argyriou | 2024/3/1 | |
Health-related quality of life in patients with ANCA vasculitides compared to rheumatoid arthritis: a cross-sectional comparative study | JCR: Journal of Clinical Rheumatology | Diego Cazzador Roberto Padoan Roberta Colangeli Alfonso Luca Pendolino Mara Felicetti | 2022/1/1 |
P97 LNMap: a curated computational resource of molecular pathways in lupus nephritis | George Sentis Chrysa Rapti Maria Grigoriou Eirini Maria Stergioti Eleftherios Chavatzas | 2024/3/1 | |
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023 | Annals of the rheumatic diseases | Kevin L Winthrop Philip Mease Andreas Kerschbaumer Reinhard E Voll Ferdinand C Breedveld | 2024/4/1 |
Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α … | Clinical and Experimental Rheumatology | Marinella Govoni Anastas Batalov Dimitrios T Boumpas Salvatore D'Angelo Filip De Keyser | 2024/3 |
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their … | Annals of the Rheumatic Diseases | Sofia Pitsigavdaki Myrto Nikoloudaki Panagiotis Garantziotis Ettore Silvagni Argyro Repa | 2024/1/17 |
O13 Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study | Panagiotis Garantziotis Georgia-Savina Moysidou Stavros Doumas Dionysis Nikolopoulos George Sentis | 2024/3/1 | |
Enhanced medullary and extramedullary granulopoiesis sustain the inflammatory response in lupus nephritis | Lupus Science & Medicine | Eleni Zervopoulou Maria Grigoriou Stavros A Doumas Danae Yiannakou Pavlos Pavlidis | 2024/3/1 |
Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection | QJM: An International Journal of Medicine | Ilona Nln Justine Shum Yogita Ghodke-Puranik Regine Tipon Danielle Triese | 2024/3/26 |
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update | GK Bertsias JPA Ioannidis M Aringer E Bollen Stefano Bombardieri | 2010/12/1 |
